<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231451</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT 038</org_study_id>
    <nct_id>NCT01231451</nct_id>
  </id_info>
  <brief_title>Depot Contraception With and Without Lopinavir/Ritonavir</brief_title>
  <official_title>The Pharmacokinetics of Depot Medroxyprogesterone Acetate (DMPA) in the Absence and Presence of Lopinavir/Ritonavir in HIV-1 Infected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DMPA (depot medroxyprogesterone acetate or the 'depot' injection) is a widely used
      contraception. It is popular in woman with HIV as it probably still works when you take HIV
      drugs. HIV drugs can increase or decrease the level of other drugs (e.g. contraceptives) in
      your bloodstream which may make them work less well or increase side effects. It is assumed
      that DMPA can be given with HIV drugs there are no studies proving this.

      The purpose of the study is to investigate whether an HIV drug combination containing
      lopinavir/ritonavir affects DMPA when they are taken at the same time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lopinavir/ritonavir (LPV/r) is licensed for use in combination with other antiretrovirals for
      the treatment of HIV infection. Like other agents from the protease inhibitor class, LPV/r
      inhibits the 3A isoenzyme of the hepatic cytochrome P450 system and may increase the levels
      of drugs metabolised via this route. However, LPV/r has also been shown in vivo to induce its
      own metabolism and to increase the biotransformation of some drugs metabolized by P450
      enzymes and by glucuronidation.

      Women account for an increasing proportion of the HIV epidemic in the UK. The huge reductions
      in HIV-related mortality and morbidity associated with the use of effective combination
      antiretroviral therapy have led to a shift in focus to longer term issues, including
      reproductive health and contraception. The impact of a variety of antiretrovirals on the
      plasma pharmacokinetics of oral oestrogen and progesterone preparations have been
      investigated and in general NNRTIs and boosted PIs cause a reduction in levels of both,
      particularly oral oestrogen preparations. Most package inserts for combined (oestrogen and
      progestogen) and progestogen-only oral contraceptives recommend that additional contraceptive
      methods be employed with concomitant use of enzyme-inducing agents.

      Injectable contraception provides highly effective contraception without the need for daily
      pill taking, an important factor to consider for individuals already taking regular
      medication. Depot medroxyprogesterone acetate (DMPA) is the most frequently prescribed
      injectable method. DMPA, like other progestogens, is metabolised by the cytochrome P450
      system but interaction studies in women on antiretrovirals are limited. A study of 59 women
      on DMPA contraception plus an unboosted PI (nelfinavir) or an NNRTI (efavirenz or nevirapine)
      measured DMPA levels and compared them with 16 women on either no therapy or NRTIs only (no
      potential for drug interaction). DMPA levels were similar in all groups and suppression of
      ovulation over a 12 week period was also similar in all groups.

      Although the high levels of DMPA achieved over the dosing interval make any pharmacokinetic
      interaction unlikely to be clinically significant, some clinicians advise a reduction in the
      interval between DMPA injections from 12 to 10 weeks in patients on an NNRTI or boosted PI;
      there is no clear evidence to support this approach. Although the described study supports
      normal dosing intervals for women on an NNRTI, the unboosted PI nelfinavir is not recommended
      as standard of care and the impact of ritonavir-boosted PIs is unclear. The summary of
      product characteristics for DMPA advises a normal dosing interval even when using a potent
      enzyme inducers, suggesting no additional intervention is required when prescribing a boosted
      PI. Formal pharmacokinetic data is crucial to clarify this important area.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Ethics board said the study could not be fully justified.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics of depot medroxyprogesterone acetate (DMPA)</measure>
    <time_frame>week 1 - week 24</time_frame>
    <description>To investigate the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) in the absence and presence of lopinavir/ritonavir in HIV-
1 infected women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of co-administration of DMPA and lopinavir/ritonavir</measure>
    <time_frame>Week 1 - week 24</time_frame>
    <description>To investigate the impact of co-administration of DMPA and lopinavir/ritonavir on surrogate markers of contraceptive efficacy (LH, FSH, oestradiol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of DMPA</measure>
    <time_frame>Week 1 - week 24</time_frame>
    <description>To investigate the safety of DMPA in HIV infected women on lopinavir/ritonavir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of DMPA on lopinavir/ritonavir plasma concentrations</measure>
    <time_frame>week 1 - week 24</time_frame>
    <description>To investigate the impact of DMPA on lopinavir/ritonavir plasma concentrations compared with historical controls</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Subjects will receive the same intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <description>All subjects will take DMPA</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The ability to understand and sign a written informed consent form, prior to
             participation in any screening procedure and must be willing to comply with all study
             requirements.

          2. Non-pregnant, non-lactating premenopausal females.

          3. No current hormonal contraception (short acting methods eg oral contraceptive pills
             and patches can be removed at screening)

          4. Regular menstrual periods such that DMPA can be administered between days 1-5 of
             menstrual cycle

          5. Between 18 and 45 years, inclusive.

          6. Documented HIV-1 infection

          7. Must be willing to use a barrier method of contraception to avoid pregnancy throughout
             the study, and for at least 56 days following completion of the study.

          8. CD4 count &gt; 200 at screening (Note: retesting of screening CD4 count allowed).

          9. Clinician and patient happy to delay HAART until week 12 of study

         10. Not currently on HAART and eligible to receive LPV/r and Truvada as determined by
             their primary HIV care provider in accordance with treatment guidelines

         11. If history of HAART exposure, no virological failure (prior drug switches allowed if
             for tolerability/toxicity/convenience of dosing).

         12. Agrees not to change regimen, outside the study recommendations, from baseline until
             end of the treatment period unless this is medically indicated as decided by the
             treating physician

        Exclusion Criteria:

          1. Any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with subject treatment, assessment, or compliance with
             the protocol. This would include any active clinically significant renal, cardiac,
             hepatic, pulmonary, vascular, metabolic disorders or malignancy.

          2. Have a body mass index (BMI) &gt;35

          3. Personal history of venous thromboembolism (VTE) or pulmonary embolism (PE)

          4. Presence of any current active AIDS defining illness (Category C conditions in the CDC
             Classification System for HIV 1993) except stable cutaneous Kaposi's Sarcoma

          5. Osteoporosis or significant risk factors for osteoporosis (alcohol abuse, long-term
             anticonvulsants/corticosteroids, BMI less than 18, eating disorder, previous low
             trauma fracture, significant family history osteoporosis)

          6. Conditions for which DMPA is contra-indicated or risks outweigh benefits:

               1. Significant multiple risk factors for arterial cardiovascular disease

               2. Vascular disease

               3. Previous or current venous thromboembolism (VTE) or pulmonary embolism (PE)

               4. Ischaemic heart disease

               5. Stroke (history of cerebrovascular accident)

               6. Headaches migraine with aura, at any age

               7. Unexplained vaginal bleeding

               8. Gestational trophoblastic neoplasia (GTN) (includes hydatidiform mole, invasive
                  mole, placental site trophoblastic tumour) hCG abnormal

               9. Breast cancer (past or current) or strong family history

              10. Diabetes nephropathy/retinopathy/neuropathy

              11. Other vascular disease or diabetes of &gt;20 years' duration

              12. Viral hepatitis (active)

              13. Presence or history of any sever hepatic disease where liver function tests have
                  not returned to normal

              14. Cirrhosis (decompensated)

          7. Clinically relevant alcohol or drug use (positive urine drug screen, excluding
             cannabinoids) or history of alcohol or drug use considered by the Investigator to be
             sufficient to hinder compliance, follow-up procedures or evaluation of adverse events.
             Smoking is permitted, but tobacco intake should remain consistent throughout the
             study.

          8. The use of disallowed concomitant therapy (See section 5.2).

          9. Previous allergy to any of the constituents of the study pharmaceuticals.

         10. Exposure to any investigational drug or placebo within 4 weeks of baseline.

         11. Any HAART exposure within 6 months of screening for this study (ie participants need
             to be treatment-na√Øve or on a treatment interruption for 6 months or more).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St Stephen's Centre</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>November 25, 2010</last_update_submitted>
  <last_update_submitted_qc>November 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Laura Waters</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

